Helix BioPharma Corp. (TSE:HBP - Get Free Report) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of C$0.96 and traded as high as C$1.08. Helix BioPharma shares last traded at C$1.08, with a volume of 32,000 shares traded.
Helix BioPharma Price Performance
The company has a 50-day moving average of C$0.97 and a two-hundred day moving average of C$0.91. The stock has a market capitalization of C$57.26 million, a PE ratio of -1.13 and a beta of -0.84.
Helix BioPharma Company Profile
(
Get Free Report)
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.
Recommended Stories
Before you consider Helix BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Helix BioPharma wasn't on the list.
While Helix BioPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
